Russia - Pharmaceutical partnership

This is a business opportunity from an overseas buyer. Pitch for the business and explain how your company meets their requirements.

An international company is looking for a partnership for licensing and manufacturing modern and legacy antibiotics.

Details

Opportunity closing date

01 July 2019

Opportunity publication date

14 February 2019

Opportunity type

Private Sector

Industry

Pharmaceuticals and biotechnology

Enquiries received

Value of contract

to be confirmed

Your guide to exporting

Report opportunity

Description

You must be able to license or manufacture antibiotics including, but not limited to:

- 1,500mg IV/IM, 750mg IV/IM, 375mg IV/IM of penicillin ampisid, and ampicillin or sulbactam
- 1,500mg IM, 750mg IM, 375mg IM of penicillin ampisid, and ampicillin or sulbactam
- 375mg tb of penicillin ampisid and sultamicillin
- 250mg suspension 40 ml to 70 ml of penicillin ampisid and sultamicillin
- 500mg IV/IM, 1000mg IV/IM of Intracef Carson and ceftriaxone
- 500mg IM, 1000mg IM of Intracef Carson and ceftriaxone
- 200mg tablets, 400mg tb of flosiprin zolfoks and ofloxacin
- 2mg/mL 100mL solution for injection of flosiprin zolfoks and ofloxacin

The company markets and sells pharmaceuticals with offices in Russia and the Commonwealth of Independent States (CIS).

It wants to partner with UK companies for license transfers or contract manufacturing under their brand.

Opportunity closing date: 01 July 2019
Value of contract: to be confirmed
The buyer is happy to talk to: manufacturers

The deadline to apply for this opportunity has passed.
Visit the opportunities page to find another.